Apr 23, 2026 08:30AM
Apr 23, 2026 08:30AM
Nov 24, 2025 08:00AM
Nov 24, 2025 08:00AM
Nov 13, 2025 06:00AM
Nov 13, 2025 06:00AM
Nov 10, 2025 07:00AM Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Nov 4, 2025 04:00PM
Aug 5, 2025 04:00PM
Jun 10, 2025 08:31AM
Jun 10, 2025 08:30AM
Jun 2, 2025 06:53AM
May 6, 2025 04:01PM
Feb 25, 2025 04:05PM Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
Jan 13, 2025 08:15AM
Jan 13, 2025 08:00AM
Oct 30, 2024 04:01PM
Jul 30, 2024 07:30AM
Jul 25, 2024 12:58AM
Jun 18, 2024 08:30AM
May 30, 2024 08:32AM Day One (DAWN) Sells Priority Review Voucher for $108M
May 30, 2024 08:30AM
May 6, 2024 04:30PM
Apr 24, 2024 10:02AM
Apr 24, 2024 09:32AM
Apr 24, 2024 07:11AM
Apr 23, 2024 03:57PM
Apr 23, 2024 03:56PM Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Apr 23, 2024 02:12PM
Feb 26, 2024 04:30PM
Nov 17, 2023 07:01AM
Nov 17, 2023 07:00AM
Nov 6, 2023 04:30PM
Oct 30, 2023 08:00AM
Sep 11, 2023 08:30AM Day One Biopharmaceuticals (DAWN) Announces Updated FIREFLY-1 Data for Tovorafenib
Sep 11, 2023 08:30AM
Aug 7, 2023 04:30PM
Jun 8, 2023 07:00AM
Jun 5, 2023 07:10AM
Jun 4, 2023 12:45PM
May 25, 2023 08:30PM
May 25, 2023 05:00PM Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 1, 2023 09:00AM
May 1, 2023 09:00AM
Apr 26, 2023 09:31AM
Apr 26, 2023 09:31AM
Apr 12, 2023 08:00AM
Apr 12, 2023 08:00AM
Mar 6, 2023 04:30PM Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
Mar 6, 2023 04:30PM

323,712 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All